DE60113733T2 - Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren - Google Patents

Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren Download PDF

Info

Publication number
DE60113733T2
DE60113733T2 DE60113733T DE60113733T DE60113733T2 DE 60113733 T2 DE60113733 T2 DE 60113733T2 DE 60113733 T DE60113733 T DE 60113733T DE 60113733 T DE60113733 T DE 60113733T DE 60113733 T2 DE60113733 T2 DE 60113733T2
Authority
DE
Germany
Prior art keywords
cyclopamine
cells
bcc
tumor
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60113733T
Other languages
German (de)
English (en)
Other versions
DE60113733D1 (de
Inventor
Sinan Tas Dr.
Avci Dr.Oktay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tas Sinan Bor Tr
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21619326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60113733(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60113733D1 publication Critical patent/DE60113733D1/de
Publication of DE60113733T2 publication Critical patent/DE60113733T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE60113733T 2001-07-02 2001-07-02 Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren Expired - Lifetime DE60113733T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2001/000027 WO2002078703A1 (en) 2001-07-02 2001-07-02 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors

Publications (2)

Publication Number Publication Date
DE60113733D1 DE60113733D1 (de) 2006-02-09
DE60113733T2 true DE60113733T2 (de) 2006-06-29

Family

ID=21619326

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60113733T Expired - Lifetime DE60113733T2 (de) 2001-07-02 2001-07-02 Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren
DE60204966T Expired - Lifetime DE60204966T2 (de) 2001-07-02 2002-04-19 Verwendung von Cyclopamin zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60204966T Expired - Lifetime DE60204966T2 (de) 2001-07-02 2002-04-19 Verwendung von Cyclopamin zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis

Country Status (14)

Country Link
EP (4) EP2862570A1 (enExample)
JP (3) JP2004536045A (enExample)
KR (1) KR20090125833A (enExample)
CN (2) CN1525859B (enExample)
AT (2) ATE305300T1 (enExample)
AU (1) AU2001272892B8 (enExample)
BR (1) BR0117063A (enExample)
CA (1) CA2452151C (enExample)
DE (2) DE60113733T2 (enExample)
DK (2) DK1401438T3 (enExample)
ES (3) ES2534400T3 (enExample)
PT (1) PT1411938E (enExample)
RU (1) RU2312661C2 (enExample)
WO (2) WO2002078703A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
ES2534400T3 (es) * 2001-07-02 2015-04-22 Sinan Tas Uso de ciclopamina en el tratamiento de carcinoma de células basales y otros tumores
US20170326118A1 (en) 2001-07-02 2017-11-16 Sinan Tas Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells
CA2452152A1 (en) 2001-07-02 2002-10-10 Sinan Tas Use of cyclopamine in the treatment of psoriasis
AU2006283040B2 (en) 2005-08-22 2011-08-25 The Johns Hopkins University Hedgehog pathway antagonists to treat disease
PT2500360E (pt) 2005-10-31 2015-10-15 Oncomed Pharm Inc Composições e métodos para diagnóstico e tratamento do cancro
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
MY181496A (en) * 2006-10-31 2020-12-23 Government Of The United States Of America Represented By The Sec Dep Of Health And Human Services Smoothened polypeptides and methods of use
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
EP2106439B1 (en) 2007-01-24 2014-11-12 The Regents of the University of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
NZ579361A (en) * 2007-03-07 2012-04-27 Infinity Discovery Inc Heterocyclic cyclopamine analogs and methods of use thereof
US7964590B2 (en) 2007-03-07 2011-06-21 Infinity Discovery, Inc. Cyclopamine lactam analogs and methods of use thereof
EP3190121B1 (en) 2007-12-27 2019-02-20 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction of cyclopamine 4-en-3-one derivative
WO2009099625A2 (en) * 2008-02-08 2009-08-13 The Board Of Regents Of The University Of Texas System Cyclopamine tartrate salt and uses thereof
MX2011003183A (es) 2008-09-26 2011-04-21 Oncomed Pharm Inc Agentes que se unen a receptor encrespado y usos de los mismos.
US20110275576A1 (en) * 2009-01-06 2011-11-10 Utah State University Carbohydrate-Cyclopamine Conjugates as Anticancer Agents
JP2009143963A (ja) * 2009-03-25 2009-07-02 Sinan Tas 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物
WO2011017551A1 (en) 2009-08-05 2011-02-10 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
KR20130043102A (ko) 2010-04-01 2013-04-29 온코메드 파마슈티칼스, 인크. 프리즐드-결합 작용제 및 그의 용도
WO2012037217A1 (en) 2010-09-14 2012-03-22 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
HK1212216A1 (en) 2012-10-23 2016-06-10 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
HK1211887A1 (en) 2013-02-04 2016-06-03 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
CN104740633A (zh) * 2013-12-26 2015-07-01 中国科学院上海生命科学研究院 Shh信号通路特异性抑制剂的应用
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
WO2017139497A1 (en) * 2016-02-11 2017-08-17 PellePharm, Inc. Hedgehog inhibitor for use in relief of and treatment of pruritus or itching
CA3227688A1 (en) 2021-09-13 2023-03-02 Sinan Tas Effective interventions with aging and diseases of aging of human and their consequences
CN114292279B (zh) * 2022-01-07 2023-05-09 吉林省农业科学院 一种藜芦抗癌有效成分环杷明提取与分离方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851993A (en) * 1994-06-13 1998-12-22 Biotie Therapies Ltd. Suppression of tumor cell growth by syndecan-1 ectodomain
US7098196B1 (en) * 1999-10-13 2006-08-29 Johns Hopkins University School Of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto
WO1999052534A1 (en) * 1998-04-09 1999-10-21 Johns Hopkins University School Of Medicine Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
ATE466850T1 (de) * 1998-09-23 2010-05-15 Res Dev Foundation Tocopherole, tocotrienole, sonstige chroman- und seitenkettenderivate, sowie deren verwendungen
US6291516B1 (en) * 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
AU780358B2 (en) * 1999-06-08 2005-03-17 Lorantis Limited Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway
EP1646395B8 (en) * 1999-11-30 2014-12-17 Curis, Inc. Methods and compositions for regulating lymphocyte activity
CU23175A1 (es) * 2000-07-17 2006-09-22 Ct De Investigacion Y Desarrol Formulacion liposomica de propionato de clobetasol
CA2452152A1 (en) * 2001-07-02 2002-10-10 Sinan Tas Use of cyclopamine in the treatment of psoriasis
ES2534400T3 (es) * 2001-07-02 2015-04-22 Sinan Tas Uso de ciclopamina en el tratamiento de carcinoma de células basales y otros tumores

Also Published As

Publication number Publication date
DE60204966T2 (de) 2006-05-18
JP2004536045A (ja) 2004-12-02
CA2452151C (en) 2012-01-03
ATE305300T1 (de) 2005-10-15
DK1401438T3 (da) 2006-02-13
BR0117063A (pt) 2004-07-27
WO2002078704A1 (en) 2002-10-10
EP1561464A3 (en) 2007-04-25
RU2004103074A (ru) 2005-05-10
AU2001272892B2 (en) 2006-03-16
ES2534400T3 (es) 2015-04-22
DE60204966D1 (de) 2005-08-11
CN1525859B (zh) 2010-05-05
KR20090125833A (ko) 2009-12-07
WO2002078703A1 (en) 2002-10-10
ES2250434T3 (es) 2006-04-16
EP1561464A2 (en) 2005-08-10
PT1411938E (pt) 2005-11-30
AU2001272892B8 (en) 2006-05-04
DK1411938T3 (da) 2005-11-07
EP1401438B1 (en) 2005-09-28
JP2010132691A (ja) 2010-06-17
JP2014028834A (ja) 2014-02-13
EP2216022B1 (en) 2015-01-07
EP2862570A1 (en) 2015-04-22
EP2216022A1 (en) 2010-08-11
CN1525859A (zh) 2004-09-01
RU2312661C2 (ru) 2007-12-20
DE60113733D1 (de) 2006-02-09
CA2452151A1 (en) 2002-10-10
ES2246011T3 (es) 2006-02-01
WO2002078703A8 (en) 2003-06-12
JP5424923B2 (ja) 2014-02-26
CN1522146A (zh) 2004-08-18
ATE299022T1 (de) 2005-07-15
EP1401438A1 (en) 2004-03-31
CN1230169C (zh) 2005-12-07

Similar Documents

Publication Publication Date Title
DE60113733T2 (de) Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren
DE60302348T2 (de) Verwendung von cyclopamine zur behandlung von psoriasis und anderen hauterkrankungen
DE69323549T2 (de) Topisch anwendbare arzneimittel, enthaltend toremifen und dessen metabolite
DE2746950C2 (enExample)
DE69327544T2 (de) Mischungen zum schutz und regenierung von geweben
DE69635488T2 (de) Antivirale verbindung
DE69332350T2 (de) Verwendung von Lycopen zur Verminderung der Zellaktivität, insbesondere von Krebszellen, sowie entsprechende pharmazeutische Zubereitungen
AU2001272892A1 (en) Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
DE69902520T2 (de) Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
DE69917796T2 (de) Decursin-enthaltende pharmazeutische zusammensetzungen
EP1056467B1 (de) Verfahren zur behandlung von erkrankungen oder störungen des innenohrs
DE1804801B2 (de) Mittel zur aknebehandlung
DE69727154T2 (de) Land- und meeressschildkrötenöle, diese enthaltende zusammensetzungen, verfahren zu deren herstellung und verwendungen
DE69607854T2 (de) Sphingosylphosphorylcholin als wirkstoff zur wundheilung
DE60035613T2 (de) Topische,kosmetische und pharmazeutische Mittel,enthaltend spezifische alkoxylierte Diester der Fumarsäure
DE3633315A1 (de) Mittel zur prophylaxe und behandlung von hautverbrennungen durch strahlen
EP4429635A1 (de) Selbstemulgierende öl-in wasser-mikro- oder nanoemulsion sowie emulgierende zusammensetzung
DE19625582A1 (de) Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen die mit einer unphysiologisch hohen Zellsterberate einhergehen
DE102013104342A1 (de) Pharmazeutische Zusammensetzung
DE69735091T2 (de) Synergistische Gold enthaltende Zusammensetzungen
DE19853425A1 (de) Khellin-Zubereitung und deren Verwendung zur topischen Therapie der Psoriasis, ihrer Subtypen, Sonderformen, sowie zur topischen Therapie von Ekzemen
DE2713105A1 (de) Dermatologisches arzneimittel
DE69922398T2 (de) Phenantrenderivate mit medizinischer anwendung sowie dessen herstellungsverfahren
LU84952A1 (de) Arzneimittel mit analgetischer wirkung
WO2003094945A1 (de) Verwendung von hyperforin und derivaten davon zur hemmung der angiogenese

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: TAS, SINAN, BOR, TR